<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anti‐vascular endothelial growth factor for neovascular glaucoma - Rittiphairoj, T - 2023 | Cochrane Library</title> <meta content="Anti‐vascular endothelial growth factor for neovascular glaucoma - Rittiphairoj, T - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007920.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anti‐vascular endothelial growth factor for neovascular glaucoma - Rittiphairoj, T - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007920.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007920.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Anti‐vascular endothelial growth factor for neovascular glaucoma" name="citation_title"/> <meta content="Thanitsara Rittiphairoj" name="citation_author"/> <meta content="thanitsara.r@gmail.com" name="citation_author_email"/> <meta content="Gloria Roberti" name="citation_author"/> <meta content="Fondazione G.B. Bietti per lo studio e la ricerca in Oftalmolologia-IRCCS" name="citation_author_institution"/> <meta content="Manuele Michelessi" name="citation_author"/> <meta content="Fondazione G.B. Bietti per lo studio e la ricerca in Oftalmolologia-IRCCS" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD007920.pub4" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/04/03" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007920.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007920.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007920.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bevacizumab [therapeutic use]; *Glaucoma, Neovascular [drug therapy]; Ranibizumab [therapeutic use]; *Vascular Endothelial Growth Factor A [antagonists &amp; inhibitors]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007920.pub4&amp;doi=10.1002/14651858.CD007920.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="p32VIvbS";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007920\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007920\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","fa","fr","pl","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007920.pub4",title:"Anti\\u2010vascular endothelial growth factor for neovascular glaucoma",firstPublishedDate:"Apr 3, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007920.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007920.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007920.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007920.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007920.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007920.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007920.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007920.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007920.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007920.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1370 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007920.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/full#CD007920-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/full#CD007920-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/full#CD007920-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/full#CD007920-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/full#CD007920-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/full#CD007920-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/full#CD007920-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/full#CD007920-sec-0084"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/appendices#CD007920-sec-0095"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/supinfo/CD007920-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/supinfo/CD007920-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anti‐vascular endothelial growth factor for neovascular glaucoma</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/information#CD007920-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Thanitsara Rittiphairoj</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/information#CD007920-cr-0005">Gloria Roberti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007920.pub4/information#CD007920-cr-0006">Manuele Michelessi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/information/en#CD007920-sec-0107">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 03 April 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007920.pub4">https://doi.org/10.1002/14651858.CD007920.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007920-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007920-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007920-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007920-abs-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007920-abs-0006">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007920-abs-0001" lang="en"> <section id="CD007920-sec-0001"> <h3 class="title" id="CD007920-sec-0001">Background</h3> <p>Neovascular glaucoma (NVG) is a potentially blinding, secondary glaucoma. It is caused by the formation of abnormal new blood vessels, which prevent normal drainage of aqueous from the anterior segment of the eye. Anti‐vascular endothelial growth factor (anti‐VEGF) medications are specific inhibitors of the primary mediators of neovascularization. Studies have reported the effectiveness of anti‐VEGF medications for the control of intraocular pressure (IOP) in NVG. </p> </section> <section id="CD007920-sec-0002"> <h3 class="title" id="CD007920-sec-0002">Objectives</h3> <p>To assess the effectiveness of intraocular anti‐VEGF medications, alone or with one or more types of conventional therapy, compared with no anti‐VEGF medications for the treatment of NVG. </p> </section> <section id="CD007920-sec-0003"> <h3 class="title" id="CD007920-sec-0003">Search methods</h3> <p>We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register); MEDLINE; Embase; PubMed; and LILACS to 19 October 2021; <i>meta</i>Register of Controlled Trials to 19 October 2021; and two additional trial registers to 19 October 2021. We did not use any date or language restrictions in the electronic search for trials. </p> </section> <section id="CD007920-sec-0004"> <h3 class="title" id="CD007920-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) of people treated with anti‐VEGF medications for NVG. </p> </section> <section id="CD007920-sec-0005"> <h3 class="title" id="CD007920-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed the search results for trials, extracted data, and assessed risk of bias, and the certainty of the evidence. We resolved discrepancies through discussion. </p> </section> <section id="CD007920-sec-0006"> <h3 class="title" id="CD007920-sec-0006">Main results</h3> <p>We included five RCTs (356 eyes of 353 participants). Each trial was conducted in a different country: two in China, and one each in Brazil, Egypt, and Japan. All five RCTs included both men and women; the mean age of participants was 55 years or older. Two RCTs compared intravitreal bevacizumab combined with Ahmed valve implantation and panretinal photocoagulation (PRP) with Ahmed valve implantation and PRP alone. One RCT randomized participants to receive an injection of either intravitreal aflibercept or placebo at the first visit, followed by non‐randomized treatment according to clinical findings after one week. The remaining two RCTs randomized participants to PRP with and without ranibizumab, one of which had insufficient details for further analysis. We assessed the RCTs to have an unclear risk of bias for most domains due to insufficient information to permit judgment.   </p> <p>Four RCTs examined achieving control of IOP, three of which reported our time points of interest. Only one RCT reported our critical time point at one month; it found that the anti‐VEGF group had a 1.3‐fold higher chance of achieving control of IOP at one month (RR 1.32, 95% 1.10 to 1.59; 93 participants) than the non‐anti‐VEGF group (low certainty of evidence). For other time points, one RCT found a three‐fold greater achievement in control of IOP in the anti‐VEGF group when compared with the non‐anti‐VEGF group at one year (RR 3.00; 95% CI:1.35 to 6.68; 40 participants). However, another RCT found an inconclusive result at the time period ranging from 1.5 years to three years (RR 1.08; 95% CI: 0.67 to 1.75; 40 participants).  </p> <p>All five RCTs examined mean IOP, but at different time points. Very‐low‐certainty evidence showed that anti‐VEGFs were effective in reducing mean IOP by 6.37 mmHg (95% CI: ‐10.09 to ‐2.65; 3 RCTs; 173 participants) at four to six weeks when compared with no anti‐VEGFs.  Anti‐VEGFs may reduce mean IOP at three months (MD ‐4.25; 95% CI ‐12.05 to 3.54; 2 studies; 75 participants), six months (MD ‐5.93; 95% CI ‐18.13 to 6.26; 2 studies; 75 participants), one year (MD ‐5.36; 95% CI ‐18.50 to 7.77; 2 studies; 75 participants), and more than one year (MD ‐7.05; 95% CI ‐16.61 to 2.51; 2 studies; 75 participants) when compared with no anti‐VEGFs, but such effects remain uncertain. </p> <p>Two RCTs reported the proportion of participants who achieved an improvement in visual acuity with specified time points. Participants receiving anti‐VEGFs had a 2.6 times (95% CI 1.60 to 4.08; 1 study; 93 participants) higher chance of improving visual acuity when compared with those not receiving anti‐VEGFs at one month (very low certainty of evidence). Likewise, another RCT found a similar result at 18 months (RR 4.00, 95% CI 1.33 to 12.05; 1 study; 40 participants).  </p> <p>Two RCTs reported the outcome, complete regression of new iris vessels, at our time points of interest. Low‐certainty evidence showed that anti‐VEGFs had a nearly three times higher chance of complete regression of new iris vessels when compared with no anti‐VEGFs (RR 2.63, 95% CI 1.65 to 4.18; 1 study; 93 participants). A similar finding was observed at more than one year in another RCT (RR 3.20, 95% CI 1.45 to 7.05; 1 study; 40 participants).  </p> <p>Regarding adverse events, there was no evidence that the risks of hypotony and tractional retinal detachment were different between the two groups (RR 0.67; 95% CI: 0.12 to 3.57 and RR 0.33; 95% CI: 0.01 to 7.72, respectively; 1 study; 40 participants). No RCTs reported incidents of endophthalmitis, vitreous hemorrhage, no light perception, and serious adverse events. Evidence for the adverse events of anti‐VEGFs was low due to limitations in the study design due to insufficient information to permit judgments and imprecision of results due to the small sample size. </p> <p>No trial reported the proportion of participants with relief of pain and resolution of redness at any time point. </p> </section> <section id="CD007920-sec-0007"> <h3 class="title" id="CD007920-sec-0007">Authors' conclusions</h3> <p>Anti‐VEGFs as an adjunct to conventional treatment could help reduce IOP in NVG in the short term (four to six weeks), but there is no evidence that this is likely in the longer term. Currently available evidence regarding the short‐ and long‐term effectiveness and safety of anti‐VEGFs in achieving control of IOP, visual acuity, and complete regression of new iris vessels in NVG is insufficient. More research is needed to investigate the effect of these medications compared with, or in addition to, conventional surgical or medical treatment in achieving these outcomes in NVG. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007920-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007920-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007920-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007920-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007920-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007920-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD007920-abs-0008">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007920-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007920-abs-0002" lang="en"> <h3>Anti‐vascular endothelial growth factor for neovascular glaucoma</h3> <p><b>What was the aim of this review?</b><br/>To compare treatment with and without anti‐vascular endothelial growth factor (anti‐VEGF) medications for people with neovascular glaucoma (NVG). </p> <p><b>Key message</b><br/>It is uncertain whether treatment with anti‐VEGF medications is more beneficial than treatment without anti‐VEGF medications for people with NVG. More research is needed to investigate the effect of anti‐VEGF medications compared with, or in addition to, conventional treatment. </p> <p><b>What did we study in this review?</b><br/>VEGF is a protein produced by cells in your body, and produces new blood vessels when needed. When cells produce too much VEGF, abnormal blood vessels can grow in the eye. NVG is a type of glaucoma where the angle between the iris (colored part of the eye) and the cornea (transparent front part of the eye) is closed by new blood vessels growing in the eye, hence, the name 'neovascular'. New blood vessels can cause scarring and narrowing, which can eventually lead to complete closure of the angle. This results in increased eye pressure since the fluid in the eye cannot drain properly. In NVG, the eye is often red and painful, and the vision is abnormal. High pressure in the eye can lead to blindness. </p> <p>Anti‐VEGF medication is a type of medicine that blocks VEGF, therefore, slowing the growth of blood vessels. It is administered by injection into the eye. It can be used at an early stage, when conventional treatment may not be possible. Most studies report short‐term (generally four to six weeks) benefits of anti‐VEGF medication, but long‐term benefits are not clear. </p> <p><b>What were the main results of this review?</b><br/>We included five studies enrolling a total of 356 eyes of 353 participants with NVG. </p> <p>Three studies reported different results for achieving control of IOP at various time points of interest. One study showed that anti‐VEGF medications were more effective at one month. In the longer term, one study reported the superiority of anti‐VEGF medications while another showed inconclusive results. Therefore, available evidence is insufficient to recommend the routine use of anti‐VEGF medication in individuals with NVG. </p> <p><b>How up‐to‐date is the review?</b><br/>We searched for studies that were published up to 19 October 2021.<br/>  </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007920-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007920-sec-0090">English</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007920-sec-0210">Français</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007920-sec-0090"></div> <h3 class="title" id="CD007920-sec-0091">Implications for practice</h3> <section id="CD007920-sec-0091"> <p>Anti‐VEGFs as an adjunct to conventional treatment could help reduce IOP in NVG in the short term (four to six weeks). However, such an effect remains uncertain in the longer term. We did not find sufficient evidence from which to draw definite conclusions regarding the benefits of the use of anti‐VEGF medications alone, or as an adjunct to existing modalities for the treatment of NVG. Likewise, evidence is inadequate to assess the differences in adverse events with or without the use of anti‐VEGF medications. </p> </section> <h3 class="title" id="CD007920-sec-0092">Implications for research</h3> <section id="CD007920-sec-0092"> <p>Future trials should target a larger sample size and adopt standardized conventional therapy and treatment groups.   </p> <p>To increase the translatability of the results into clinical practice, a therapeutic algorithm should be clearly defined, thus involving the time of the injection in NVG management (i.e. how many days before surgery), the site of the injection, additional therapy, and the number of injections during the follow‐up. </p> <p>Moreover, randomization in future trials should be stratified by underlying etiology for NVG or proliferative diabetic retinopathy, and the extent of peripheral anterior synechiae or angle closure, because both factors may modify the effectiveness of treatment, and imbalance in either could confound the results. </p> <p>Lastly, using a core outcome set (mean IOP and regression of new iris vessels) measured at standardized time of follow‐up would allow data to be combined in a meta‐analysis. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007920-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007920-sec-0008"></div> <div class="table" id="CD007920-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Anti‐VEGF versus no anti‐VEGF for neovascular glaucoma</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Anti‐VEGF medication compared with no anti‐VEGF medication for neovascular glaucoma</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with neovascular glaucoma<br/><b>Setting:</b> ophthalmology hospital or clinic<br/><b>Intervention:</b> intravitreal anti‐VEGF medication injection<br/><b>Comparison:</b> no anti‐VEGF medication </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no anti‐VEGF</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with anti‐VEGF</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of participants with IOP ≤ 21 mmHg, with or without ocular hypotensive medications, </p> <p>4 to 6 weeks follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>723 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>954 per 1000</b> (795 to 1150) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.32</b><br/>(95% CI 1.10 to 1.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean IOP, 4 to 6 weeks follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean IOP in the no anti‐VEGF group was <b>24.2 mm Hg</b>, </p> <p>ranged from 23.6 to 24.8 mm Hg</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean IOP in the anti‐VEGF group was <b>17.8 mm Hg</b>, </p> <p>ranged from 14.1 to 21.6 mm Hg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD ‐6.37</b> (95% CI ‐10.09 to ‐2.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>173 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of participants with improvement in visual acuity of 2 ETDRS lines or 0.2 logMAR units, 4 to 6 weeks follow‐up </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>298 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>760 per 1000</b> (477 to 1216) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.55</b><br/>(95% CI 1.60 to 4.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The trial did not clearly specify a definition of the improvement in visual acuity</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of participants with complete regression of new iris vessels,</p> <p>4 to 6 weeks follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>298 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>784 per 1000</b> (492 to 1246) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.63</b><br/>(95% CI 1.65 to 4.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝ Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with relief of pain and resolution of redness,</p> <p>1 year follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p> </p> <p> </p> <p>Included studies did not report data for this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Proportion of participants with adverse events at</p> <p>various follow‐up times</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Hypotony (IOP ≤ 6 mmHg)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p><b>15 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 100</b> (2 to 54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.67</b><br/>(95% CI 0.12 to 3.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The follow‐up period was 18 months.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Tractional retinal detachment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>5 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>2 per 100</b> (0 to 39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.33</b><br/>(95% CI 0.01 to 7.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The follow‐up period was 24 months.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Serious adverse events (e.g. systemic thrombosis, stroke, and coronary thrombosis)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Included studies did not report data for this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> reported an occurrence of serious ocular treatment‐emergent adverse events in both groups during the non‐randomized period, where participants could receive both sham injection and aflibercept injection if the re‐treatment criteria were met.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>Anti‐VEGF:</b> anti‐vascular endothelial growth factor; <b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>MD:</b> mean difference; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded (‐1) due to limitations in the design<br/><sup>b</sup>Downgraded (‐1) due to imprecision of results </p> <p><sup>c</sup>Downgraded (‐1) due to inconsistency<br/><sup>d</sup>Downgraded (‐1) due to indirectness of evidence </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007920-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007920-sec-0009">English</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007920-sec-0129">Français</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD007920-sec-0009"></div> <section id="CD007920-sec-0010"> <h3 class="title" id="CD007920-sec-0010">Description of the condition</h3> <p>Neovascular glaucoma (NVG) is a secondary glaucoma in which new vessels, and subsequently fibrous tissue, form in the anterior chamber angle of the eye. This leads to blockage of the angle, which inhibits aqueous drainage, causing elevated intraocular pressure (IOP). This condition was described as early as 1871 (<a href="./references#CD007920-bbs2-0063" title="PagenstecherH . Contribution to the teachings of hemorrhagic glaucoma [Beitrage zur lehre vom hämorrhagischen glaucom]. Graefe's Archive for Clinical and Experimental Ophthalmology1871;17:98-130.">Pagenstecher 1871</a>; <a href="./references#CD007920-bbs2-0069" title="TsaiJC , WandM . Chapter 213: Neovascular glaucoma. In: AlmA , GrosskreutzC , editors(s). Albert and Jakobiec's Principles and Practice of Ophthalmology. 3rd edition. Vol. 2. Canada: Saunders Elsevier, 2008:2689.">Tsai 2008</a>). Historically, it has also been referred to as rubeotic glaucoma, hemorrhagic glaucoma, thrombotic glaucoma, congestive glaucoma, and diabetic hemorrhagic glaucoma. </p> <p>Clinical conditions causing retinal ischemia, such as proliferative diabetic retinopathy (PDR), central retinal vein occlusion (CRVO), and ocular ischemic syndrome, are associated with NVG. The condition can be unilateral or bilateral, depending on the underlying cause for the NVG. Diabetic retinopathy is usually bilateral; CRVO is usually unilateral. Retinal ischemia results in the release of angiogenic factors, such as vascular endothelial growth factor (VEGF). The angiogenic factors diffuse into the aqueous and anterior segment, and trigger neovascularization of the iris and anterior chamber angle. This process leads to fibrous tissue proliferation, and subsequent synechial angle closure (closure of the angle because the iris is adhering to the cornea). Increased levels of VEGF have been measured in the aqueous of people with NVG (<a href="./references#CD007920-bbs2-0033" title="AielloLP , AveryRL , ArriggPG , KeytBA , JampelHD , ShahST , et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine1994;331(22):1480-7.">Aiello 1994</a>; <a href="./references#CD007920-bbs2-0067" title="SoneH , OkudaY , KawakamiY , HanataniM , SuzukiH , KozawaT , et al. Vascular endothelial growth factor level in aqueous humor of diabetic patients with rubeotic glaucoma is markedly elevated. Diabetes Care1996;19(11):1306-7.">Sone 1996</a>; <a href="./references#CD007920-bbs2-0068" title="TripathiRC , LiJ , TripathiBJ , ChalamKV , AdamisAP . Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology1998;105(2):232-7.">Tripathi 1998</a>). Elevated IOP is a direct result of secondary angle closure glaucoma. </p> <p>NVG is a potentially devastating glaucoma. Delayed diagnosis or poor management can result in complete loss of vision, with intractable pain. It is imperative to diagnose it early, and treat it immediately and aggressively. In managing NVG, it is essential to treat both the elevated IOP and the underlying cause of the disease. </p> <p>General principles for treating people with NVG include identifying the underlying etiology, controlling or eliminating retinal ischemia and reducing the IOP. Panretinal photocoagulation (PRP) ablates the ischemic retina by shrinking and eliminating the abnormal blood vessels. When most of the angle is closed due to synechiae, consequent to the angle neovascularization, medical and/or surgical treatment is necessary to control IOP. Surgical procedures for treating NVG are: trabeculectomy, implantation of aqueous drainage devices (<a href="./references#CD007920-bbs2-0060" title="MincklerD , VedulaSS , LiT , MathewM , AyyalaR , FrancisB . Aqueous shunts for glaucoma. Cochrane Database of Systematic Reviews2006, Issue 2. Art. No: CD004918. [DOI: 10.1002/14651858.CD004918.pub2]">Minckler 2006</a>; <a href="./references#CD007920-bbs2-0074" title="YalvacIS , EksiogluU , SatanaB , DumanS . Long-term results of Ahmed glaucoma valve and Molteno implant in neovascular glaucoma. Eye2007;21(1):65-70.">Yalvac 2007</a>), Nd‐Yag cyclophotocoagulation (<a href="./references#CD007920-bbs2-0040" title="DelgadoMF , DickensCJ , IwachAG , NovackGD , NychkaDS , WongPC , et al. Long-term results of noncontact neodymium:yttrium-aluminum-garnet cyclophotocoagulation in neovascular glaucoma. Ophthalmology2003;110(5):895-9.">Delgado 2003</a>), vitrectomy with PRP and trabeculectomy (<a href="./references#CD007920-bbs2-0058" title="KiuchiY , NakaeK , SaitoY , ItoS , ItoN . Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology2006;244(12):1627-32.">Kiuchi 2006</a>), and cyclocryotherapy (<a href="./references#CD007920-bbs2-0059" title="KovacicZ , IvanisevicM , RogosicV , PlavecA , KarelovicD . Cyclocryocoagulation in treatment of neovascular glaucoma [Ciklokriokoagulacija u lijecenju neovaskularnoga glaukoma]. Lijecnicki Vjesnik2004;126(9-10):240-2.">Kovacic 2004</a>). They may be done in conjunction with anti‐metabolites, such as 5‐fluorouracil or mitomycin C, which modify wound healing and reduce scarring (<a href="./references#CD007920-bbs2-0071" title="WilkinsM , IndarA , WormaldR . Intraoperative mitomycin C for glaucoma surgery. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD002897. [DOI: 10.1002/14651858.CD002897.pub2]">Wilkins 2005</a>; <a href="./references#CD007920-bbs2-0073" title="WormaldR , WilkinsM , BunceC . Postoperative 5-fluorouracil for glaucoma surgery. Cochrane Database of Systematic Reviews2001, Issue 3. Art. No: CD001132. [DOI: 10.1002/14651858.CD001132]">Wormald 2001</a>). </p> </section> <section id="CD007920-sec-0011"> <h3 class="title" id="CD007920-sec-0011">Description of the intervention</h3> <p>Currently, anti‐VEGF medications are used for various conditions in which hypoxia‐induced VEGF release and subsequent neovascularization lead to ocular damage. Initially used in ophthalmology for the treatment of choroidal neovascularization in age‐related macular degeneration (<a href="./references#CD007920-bbs2-0066" title="SolomonSD , LindsleyK , VedulaSS , KrzystolikMG , HawkinsBS . Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews2019, Issue 3. Art. No: CD005139. [DOI: 10.1002/14651858.CD005139.pub4]">Solomon 2019</a>), the application of anti‐VEGF medications has expanded rapidly to include treatment for other conditions, such as NVG, diabetic macular edema, and retinopathy of prematurity (<a href="./references#CD007920-bbs2-0034" title="AndreoliCM , MillerJW . Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Current Opinion in Ophthalmology2007;18(6):502-8. [PMID: 18163003]">Andreoli 2007</a>). Some of the anti‐VEGF medications most frequently used in the eye are bevacizumab, ranibizumab, pegaptanib sodium, and aflibercept (VEGF Trap‐eye). </p> </section> <section id="CD007920-sec-0012"> <h3 class="title" id="CD007920-sec-0012">How the intervention might work</h3> <p>In treating NVG, it is critical to address the underlying pathology – angiogenic factors released by the ischemic retina. The issue of retinal ischemia can be addressed by PRP, which ablates the ischemic retina and reduces further production of angiogenic medications. However, in many people, the view of the fundus is poor, due to corneal edema or vitreous hemorrhage and, therefore, precludes PRP. Hence, interventions aimed at directly blocking angiogenic factors could help reduce the formation of new vessels, and possibly reverse the neovascularization (<a href="./references#CD007920-bbs2-0034" title="AndreoliCM , MillerJW . Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Current Opinion in Ophthalmology2007;18(6):502-8. [PMID: 18163003]">Andreoli 2007</a>; <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0068" title="TripathiRC , LiJ , TripathiBJ , ChalamKV , AdamisAP . Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology1998;105(2):232-7.">Tripathi 1998</a>). Intraocular injection of bevacizumab has been shown to reduce the levels of VEGF in the aqueous (<a href="./references#CD007920-bbs2-0046" title="GroverS , GuptaS , SharmaR , BrarVS , ChalamKV . Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. British Journal of Ophthalmology2009;93(2):273-4.">Grover 2009</a>). </p> <p>In eyes in which PRP can be done, variable times for regression of new vessels have been reported, and the newly formed vessels may not regress until four to six weeks after treatment. In one study, Doft and Blankenship reported regression of new vessels in 20% of participants at three days, 50% at two weeks, 72% at three weeks, and 62% at six months (<a href="./references#CD007920-bbs2-0041" title="DoftBH , BlankenshipG . Retinopathy risk factor regression after laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology1984;91(12):1453-7.">Doft 1984</a>). In another study, Blankenship reported regression in 97% of participants at one month (<a href="./references#CD007920-bbs2-0037" title="BlankenshipGW . A clinical comparison of central and peripheral argon laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology1988;95(2):170-7.">Blankenship 1988</a>). Comparison of studies is difficult, due to variation in the laser treatments, variation in the response to laser between type 1 and 2 diabetics, and the variation in the definition of substantial regression in different studies. </p> <p>On the other hand, anti‐VEGF medications have been shown to cause regression of new vessels in the anterior chamber angle and a drop in IOP within a few days (<a href="./references#CD007920-bbs2-0036" title="AveryRL . Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina2006;26(3):352-4.">Avery 2006</a>; <a href="./references#CD007920-bbs2-0055" title="IlievME , DomigD , Wolf-SchnurrburschU , WolfS , SarraGM . Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. American Journal of Ophthalmology2006;142(6):1054-6.">Iliev 2006</a>). Intravitreal (<a href="./references#CD007920-bbs2-0055" title="IlievME , DomigD , Wolf-SchnurrburschU , WolfS , SarraGM . Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. American Journal of Ophthalmology2006;142(6):1054-6.">Iliev 2006</a>; <a href="./references#CD007920-bbs2-0075" title="YazdaniS , HendiK , PakravanM . Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. Journal of Glaucoma2007;16(5):437-9.">Yazdani 2007</a>), and less commonly, intracameral (<a href="./references#CD007920-bbs2-0046" title="GroverS , GuptaS , SharmaR , BrarVS , ChalamKV . Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. British Journal of Ophthalmology2009;93(2):273-4.">Grover 2009</a>) anti‐VEGF medications have been used in the management of NVG to control angiogenesis in the angle and iris. However, the effects of anti‐VEGF medications for treating NVG are temporary, generally lasting four to six weeks (<a href="./references#CD007920-bbs2-0070" title="WakabayashiT , OshimaY , SakaguchiH , IkunoY , MikiA , GomiF , et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology2008;115(9):1571-80.">Wakabayashi 2008</a>). Thus, many studies have combined the use of anti‐VEGF medications with traditional treatments, such as PRP (<a href="./references#CD007920-bbs2-0043" title="EhlersJP , SpirnMJ , LamA , SivalingamA , SamuelMA , TasmanW . Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina2008;28(5):696-702.">Ehlers 2008</a>; <a href="./references#CD007920-bbs2-0048" title="HaJY , LeeTH , SungMS , ParkSW . Efficacy and safety of intracameral bevacizumab for treatment of neovascular glaucoma. Korean Journal of Ophthalmology2017;31(6):538-47.">Ha 2017</a>), with or without other surgery (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0047" title="GuptaV ,  JhaR ,  RaoA ,  KongG ,  SihotaR . The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. European Journal of Ophthalmology2009;19(3):435–41.">Gupta 2009</a>; <a href="./references#CD007920-bbs2-0057" title="KangJY , NamKY , LeeSJ , LeeSU . The effect of intravitreal bevacizumab injection before Ahmed valve implantation in patients with neovascular glaucoma. International Ophthalmology2014;34(4):793-9.">Kang 2014</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>; <a href="./references#CD007920-bbs2-0061" title="NoorNA , MustafaS , ArtiniW . Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience. Clinical Ophthalmology2017;11:1417-22.">Noor 2017</a>; <a href="./references#CD007920-bbs2-0062" title="OlmosLC , SayedMS , MoraczewskiAL , GeddeSJ , RosenfeldPJ , ShiW , et al. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. Eye2016;30(3):463-72.">Olmos 2016</a>; <a href="./references#CD007920-bbs2-0070" title="WakabayashiT , OshimaY , SakaguchiH , IkunoY , MikiA , GomiF , et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology2008;115(9):1571-80.">Wakabayashi 2008</a>; <a href="./references#CD007920-bbs2-0072" title="WittstromE , HolmbergH , HvarfnerC , AndreassonS . Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab. European Journal of Ophthalmology2012;22(4):563-74.">Wittstrom 2012</a>; <a href="./references#CD007920-bbs2-0076" title="YazdaniS , HendiK , PakravanM , MahdaviM , YaseriM . Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. Journal of Glaucoma2009;18(8):632-7.">Yazdani 2009</a>). </p> </section> <section id="CD007920-sec-0013"> <h3 class="title" id="CD007920-sec-0013">Why it is important to do this review</h3> <p>Various case reports, prospective and retrospective case series, and a few randomized controlled trials (RCTs) have shown good short‐term benefit of anti‐VEGF use in NVG, when combined with conventional treatment that included PRP and IOP‐lowering procedures, such as trabeculectomy, insertion of aqueous drainage devices, cyclocryotherapy and Nd Yag cyclophotocoagulation. These studies reported better regression of iris new vessels and reduced postoperative incidence of hyphema. However, the sustained long‐term benefit of better IOP control and improved visual outcomes is not clear; while a few studies showed better outcomes, most studies showed no difference with the use of anti‐VEGF medications. Variation in participant allocation, number and doses of anti‐VEGF injections, and conventional treatment used in the studies makes comparison difficult. </p> <p>On the basis of studies that showed that ischemic CRVO tends to eventually subside to a state of quiescence (<a href="./references#CD007920-bbs2-0049" title="HayrehSS . Management of central retinal vein occlusion. Ophthalmologica2003;217(3):167-88.">Hayreh 2003</a>), <a href="./references#CD007920-bbs2-0044" title="GandhiJS . Use of antivascular agents for neovascular glaucoma: benefits beyond pressure?Clinical and Experimental Ophthalmology2008;36(1):102-3.">Gandhi 2008</a> suggested that anti‐VEGF medications alone can treat NVG secondary to CRVO effectively. In two participants with CRVO who had persisting neovascularization and high IOP in spite of PRP, <a href="./references#CD007920-bbs2-0075" title="YazdaniS , HendiK , PakravanM . Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. Journal of Glaucoma2007;16(5):437-9.">Yazdani 2007</a> reported regression of new vessels and control of IOP following intravitreal bevacizumab. Maintenance of IOP control was reported for as long as six months following a second dose of intravitreal bevacizumab in both of these participants, one at eight weeks, and the other at six weeks. So the question arises about the effectiveness of anti‐VEGF in managing NVG in both the short and long term. </p> <p>A previous version of this review (<a href="./references#CD007920-bbs2-0080" title="SimhaA , AzizK , BraganzaA , AbrahamL , SamuelP , LindsleyKB . Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database of Systematic Reviews2020, Issue 2. Art. No: CD007920. [DOI: 10.1002/14651858.CD007920.pub3]">Simha 2020</a>) did not find any evidence to draw conclusions regarding the long‐term benefits of the use of intraocular anti‐VEGF for NVG treatment and suggested the need for further RCTs.  </p> <p> </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007920-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007920-sec-0014">English</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007920-sec-0134">Français</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007920-sec-0014"></div> <p>To assess the effectiveness of intraocular anti‐vascular endothelial growth factor (VEGF) medications, alone or with one or more types of conventional therapy, compared with no anti‐VEGF medications for the treatment of neovascular glaucoma. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007920-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007920-sec-0015">English</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007920-sec-0135">Français</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007920-sec-0015"></div> <section id="CD007920-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007920-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included RCTs only.</p> </section> <section id="CD007920-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies of people with NVG. We included all age groups and ocular comorbidities.</p> </section> <section id="CD007920-sec-0019"> <h4 class="title">Types of interventions</h4> <section id="CD007920-sec-0020"> <h5 class="title">Intervention group</h5> <p>People with NVG who received intraocular anti‐VEGF medications, with one or more types of conventional therapy, which included laser PRP, trabeculectomy, insertion of aqueous drainage devices, cyclophotocoagulation, cryotherapy, and medical therapy. </p> <p>In the subgroup of people with NVG due to CRVO, the intervention group could receive intraocular anti‐VEGF injection alone, without additional conventional therapy. </p> </section> <section id="CD007920-sec-0021"> <h5 class="title">Control group</h5> <p>People who underwent the same conventional therapy as the intervention group, but without intraocular anti‐VEGF medications. </p> <p>In the subgroup of people with NVG due to CRVO, the control group could receive placebo injections, or no treatment, including no conventional therapy. </p> <p>We did not include dosing studies, in which one dose of anti‐VEGF medication was compared to another dose, unless the study also had a control arm. </p> </section> </section> <section id="CD007920-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD007920-sec-0023"> <h5 class="title">Primary outcomes</h5> <p>The critical outcome of this review was the proportion of participants who achieved control of IOP, measured at four to six weeks after treatment. Control of IOP was defined as IOP ≤ 21 mmHg, with or without ocular hypotensive medications. </p> </section> <section id="CD007920-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p>We examined each important outcome described below at four to six weeks, three months, six months, one year, and thereafter as available throughout follow‐up. </p> <section id="CD007920-sec-0025"> <h6 class="title">IOP</h6> <p> <ul id="CD007920-list-0001"> <li> <p>Proportion of participants with IOP ≤ 21 mmHg, with or without ocular hypotensive medications or other treatment at three months, six months, one year, and thereafter as available throughout follow‐up </p> </li> <li> <p>Mean IOP, with or without ocular hypotensive medications</p> </li> </ul> </p> </section> <section id="CD007920-sec-0026"> <h6 class="title">Visual acuity</h6> <p> <ul id="CD007920-list-0002"> <li> <p>Proportion of participants with improvement in visual acuity</p> </li> </ul> </p> </section> <section id="CD007920-sec-0027"> <h6 class="title">Regression of new vessels</h6> <p> <ul id="CD007920-list-0003"> <li> <p>Proportion of participants with complete regression of new iris vessels</p> </li> </ul> </p> </section> <section id="CD007920-sec-0028"> <h6 class="title">Relief of symptoms</h6> <p> <ul id="CD007920-list-0004"> <li> <p>Proportion of participants with relief of pain and resolution of redness</p> </li> </ul> </p> </section> <section id="CD007920-sec-0029"> <h6 class="title">Adverse events</h6> <p> <ul id="CD007920-list-0005"> <li> <p>Infection: proportion of participants with intraocular infection or inflammation (endophthalmitis) within six weeks of the intervention </p> </li> <li> <p>Low IOP (hypotony): proportion of participants with IOP ≤ 6 mmHg</p> </li> <li> <p>Vitreous hemorrhage: proportion of participants with development of vitreous hemorrhage</p> </li> <li> <p>Tractional retinal detachment: proportion of participants who experienced tractional retinal detachment </p> </li> <li> <p>No light perception: proportion of participants with no light perception</p> </li> <li> <p>Other serious adverse events, including systemic thrombosis, stroke and coronary thrombosis, up to one‐year follow‐up </p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD007920-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007920-sec-0031"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist updated searches in the following electronic databases for RCTs and controlled clinical trials. There were no restrictions on language or year of publication. The electronic databases were last searched on 21 Oct 2021. The last search of <i>meta</i>Register of Controlled Trials was on 13 August 2013. </p> <p> <ul id="CD007920-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 10), which contains the Cochrane Eyes and Vision Trials Register, in the Cochrane Library (searched 21 Oct 2021; <a href="./appendices#CD007920-sec-0096">Appendix 1</a>); </p> </li> <li> <p>MEDLINE Ovid (1946 to 21 Oct 2021; <a href="./appendices#CD007920-sec-0097">Appendix 2</a>); </p> </li> <li> <p>Embase.com (1947 to 21 Oct 2021; <a href="./appendices#CD007920-sec-0098">Appendix 3</a>); </p> </li> <li> <p>PubMed (1948 to 21 Oct 2021; <a href="./appendices#CD007920-sec-0099">Appendix 4</a>); </p> </li> <li> <p>Latin American and Caribbean Health Sciences Literature Database (LILACS; 1982 to 21 Oct 2021; <a href="./appendices#CD007920-sec-0100">Appendix 5</a>); </p> </li> <li> <p><i>meta</i> Register of Controlled Trials (<i>m</i>RCT; <a href="http://www.controlled-trials.com" target="_blank">www.controlled-trials.com</a>; searched 13 August 2013; <a href="./appendices#CD007920-sec-0101">Appendix 6</a>), the service of which was discontinued in 2014. </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 21 Oct 2021; <a href="./appendices#CD007920-sec-0102">Appendix 7</a>); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; <a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>; searched 21 Oct 2021; <a href="./appendices#CD007920-sec-0103">Appendix 8</a>). </p> </li> </ul> </p> </section> <section id="CD007920-sec-0032"> <h4 class="title">Searching other resources</h4> <p>We handsearched the reference lists of eligible studies to identify other potentially relevant trials. We contacted investigators of ongoing studies for information about ongoing studies. </p> </section> </section> <section id="CD007920-sec-0033"> <h3 class="title" id="CD007920-sec-0033">Data collection and analysis</h3> <section id="CD007920-sec-0034"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently screened the titles and abstracts of all the reports of studies identified by the electronic searches, and handsearching, using <a href="./references#CD007920-bbs2-0038" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 1 May 2019. Available at covidence.org.">Covidence</a> (<a href="./references#CD007920-bbs2-0038" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 1 May 2019. Available at covidence.org.">Covidence</a>). Each review author classified the studies as: (1) definitely include (Yes), (2) possibly include (Maybe), and (3) definitely exclude (No). Each review author obtained and independently assessed the full‐text report(s) of each study classified by either review author as (1) or (2), and reclassified them as: (a) include, (b) awaiting classification, or (c) exclude. For reports from studies classified as (b), we attempted to contact study investigators for clarification. The two review authors compared their individual classifications and discussed discrepancies. When they could not reach consensus after discussion, a third review author reclassified the studies. We documented all studies classified as (c) exclude, and took note of any studies that are currently ongoing. We retrieved and reviewed all pertinent references from each potentially relevant study, in order to provide the most complete published information about study design, methods, and findings. </p> </section> <section id="CD007920-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data from included studies, using <a href="./references#CD007920-bbs2-0038" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 1 May 2019. Available at covidence.org.">Covidence</a>. We resolved all discrepancies through discussion. One review author entered data into Review Manager 5, and a second review author verified the data entries (<a href="./references#CD007920-bbs2-0064" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <p>Categories of information extracted for each study included: methods (study design, number of participants, and setting), intervention details, outcomes (definitions and time points), and results for each outcome (sample size, missing data, summary data for each intervention). </p> </section> <section id="CD007920-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias as recommended in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007920-bbs2-0050" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011a</a>). We provided judgment for each domain as low risk of bias, high risk of bias, or unclear risk of bias, which indicated either lack of information or uncertainty over the potential for bias. Specific criteria for assessing risk of bias focused on adequate sequence generation; allocation concealment; masking (blinding) of study participants, personnel, and outcome assessors; adequate handling of incomplete outcome data; absence of selective outcome reporting; and absence of other potential sources of bias. We attempted to contact the principal investigators if information was insufficient to judge risk of bias. </p> </section> <section id="CD007920-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>Data analysis followed guidelines set forth in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007920-bbs2-0039" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Deeks 2011</a>). </p> <p>We had planned to present dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs) for the following outcomes: </p> <p> <ul id="CD007920-list-0007"> <li> <p>The proportion of participants with control of IOP (defined as IOP ≤ 21 mmHg, with or without ocular hypotensive medications); </p> </li> <li> <p>The proportion of participants with improvement in visual acuity of 2 ETDRS lines or 0.2 logMAR units; </p> </li> <li> <p>The proportion of participants with complete regression of new iris vessels;</p> </li> <li> <p>The proportion of participants with relief of pain and resolution of redness;</p> </li> <li> <p>The proportion of participants with an adverse event.</p> </li> </ul> </p> <p>In the absence of dichotomous data, we reported continuous IOP values as means with standard deviations, when data were available. </p> </section> <section id="CD007920-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the affected eye of an individual participant. We documented studies that included participants with bilateral NVG, and used data based on the individual when possible (e.g. average of both eyes or one eye selected per participant). When data were not available based on the individual, or appropriate methods were not used to account for paired data due to the correlation between eyes, we extracted the data as reported, and performed a sensitivity analysis if we planned to include the data in a meta‐analysis. </p> </section> <section id="CD007920-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>We consulted the guidelines in Chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to inform the analysis of studies with missing data (<a href="./references#CD007920-bbs2-0051" title="HigginsJPT , DeeksJJ , AltmanDG , editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011b</a>). Where data were missing due to loss of follow‐up, or there was a mismatch between reported time endpoints and our endpoints of interest, we conducted a primary analysis based on the data as reported. Where essential data needed for statistical analysis were incomplete or missing, we attempted to contact the principal investigators for details. Whenever possible, outcome data were derived from the study reports, and we described any assumptions made when extracting data. We did not impute data for the purposes of this review. </p> </section> <section id="CD007920-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity by examining study characteristics, and forest plots of the results. We used the I² value to assess the impact of statistical heterogeneity, interpreting an I² value of 50% or more as substantial. </p> </section> <section id="CD007920-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not examine small study effects using funnel plots, as we did not perform a meta‐analysis. We assessed incomplete outcome reporting at the trial level as part of the Risk of bias assessment. </p> </section> <section id="CD007920-sec-0042"> <h4 class="title">Data synthesis</h4> <p>We conducted a meta‐analysis for the mean IOP outcome, in spite of the high I<sup>2</sup> value, as there was no significant clinical or methodological heterogeneity across RCTs. For the other outcomes, we did not conduct a meta‐analysis but reported results qualitatively and in tabular form only, due to substantial heterogeneity amongst trials.<br/>  </p> </section> <section id="CD007920-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform subgroup analysis on the primary outcome by numbers of injections administered to participants and route of administration (intracamerular versus intravitreal) to identify the best therapeutic protocol to be adopted, in terms of the number of injections and route of administration.  </p> </section> <section id="CD007920-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform sensitivity analysis to investigate the influence of studies with quasi‐random allocation methods, or those without masking of participants, providers, or outcome assessors, on the overall estimates of effect. </p> </section> <section id="CD007920-sec-0045"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared a Summary of findings table with the following outcomes of interest at one‐year follow‐up: (1) the proportion of participants who achieved control of IOP defined as IOP ≤ 21 mmHg, with or without ocular hypotensive medications, (2) mean IOP, (3) the proportion of participants with improvement in visual acuity of 2 ETDRS lines or 0.2 logMAR units, (4) the proportion of participants with complete regression of new iris vessels, (5) the proportion of participants with relief of pain and resolution of redness, and (6) the proportion of participants with adverse events. As a post hoc decision, we also included mean IOP at one year (see <a href="#CD007920-sec-0111">Differences between protocol and review</a>). We assessed the certainty of evidence for each quantitative outcome by using the GRADE classification system (<a href="./references#CD007920-bbs2-0045" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence prime), accessed 2 January 2019. Available at gradepro.org.">GRADEpro GDT</a>). We graded the certainty of evidence as very low, low, moderate, or high, based on these five criteria: risk of bias, imprecision, inconsistency, indirectness, and publication bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007920-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007920-sec-0046">English</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007920-sec-0166">Français</a> </li> </nav> </div> </div> <section class="results" lang="en"> <div class="section-header" id="CD007920-sec-0046"></div> <section id="CD007920-sec-0047"> <h3 class="title">Description of studies</h3> <section id="CD007920-sec-0048"> <h4 class="title">Results of the search</h4> <p>According to the electronic searches of the previous version of the review as of 22 March 2019, we had already included six reports of four studies (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>; NCT02396316), and one ongoing trial (<a href="./references#CD007920-bbs2-0022" title="NCT02914626. Intravitreal ranibizumab (Lucentis®) for neovascular glaucoma - a randomized controlled study. clinicaltrials.gov/ct2/show/NCT02914626 (first received 26 September 2016). ">NCT02914626</a>), which was further excluded in the updated review due to being a not completed or confirmed study. </p> <p>For this version of the review, we updated the electronic searches on 19 October 2021, and identified 395 unique records (<a href="#CD007920-fig-0001">Figure 1</a>). Of these, we excluded 366 records after screening the titles and abstracts, and assessed 29 full‐text reports for eligibility. Of 29 total records, we excluded a further 26 records; we included three records of two unique RCTs (<a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>; <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a>), one of which (<a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a>) was the same study as the previously included one (NCT02396316). Ultimately, we included five trials (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>; <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a>; <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>) for the updated version of this review.  </p> <div class="figure" id="CD007920-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram" data-id="CD007920-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> </div> </section> <section id="CD007920-sec-0049"> <h4 class="title">Included studies</h4> <section id="CD007920-sec-0050"> <h5 class="title">Types of studies</h5> <p>We included five RCTs that met the inclusion criteria, and summarized the details for each (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>; <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a>; <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>) in the '<a href="./references#CD007920-sec-0113" title="">Characteristics of included studies</a>' table. All RCTs were of parallel‐group design, except for <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a>, which applied parallel‐group design only during the first week; after week one, the study applied a non‐randomized design where participants in the sham group were allowed to receive anti‐VEGF injections if meeting re‐treatment criteria. Of all five RCTs, the maximum planned or stated length of follow‐up varied from one month (<a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>), to 13 weeks (<a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a>), to 18 months (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>), and 24 months (<a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>). Two RCTs, both multicentered studies, were registered in a clinical trials registry (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> and <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a>). Results for <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>, <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>, <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a>, and <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a> came from journal publications. All were published in English, except <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a> and <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a>, which were published in Chinese. <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a> and <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a> declared no conflict of interest, and did not report information about a funding source; <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a> did not report the source of funding nor conflict of interest; <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> was an unfunded study; and <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> was sponsored by Bayer and Regeneron Pharmaceuticals. </p> </section> <section id="CD007920-sec-0051"> <h5 class="title">Types of participants</h5> <p>All together, the five RCTs enrolled 356 eyes of 353 adult participants with uncontrolled NVG from China (<a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a> and <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a>), Brazil (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>), Egypt (<a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>), and Japan (<a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a>). All five RCTs included both men and women; the mean age of participants was 55 years or older. In <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a> and <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>, the numbers of participants who had CRVO or PDR as the underlying cause for NVG at baseline were comparable between the intervention and control groups. In <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a>, while the number of participants who had PDR and ocular ischemic syndrome as the underlying cause for NVG at baseline was comparable between groups, approximately twice as many participants in the intervention group had CRVO or other conditions at baseline. Data on the underlying cause for NVG were unavailable in the remaining two RCTs. </p> <p><a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> required that all participants underwent PRP at least two weeks before enrolment; <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> required an administration of a combination of three topical IOP‐lowering drugs during a run‐in phase before the first treatment; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a> also recruited participants undergoing PRP, but did not specify the exact timing. In <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>, mean preoperative IOP was 40.10 mmHg (standard deviation [SD] 13.33) in the anti‐VEGF group, and 38.35 mmHg (SD 10.34) in the control group; in <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>, it was 38.4 mmHg (SD 4.7) in the anti‐VEGF group, and 38.5 mmHg (SD 7.5) in the control group. Similarly, <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> reported mean preoperative IOP of 33 mmHg (SD 10) in the anti‐VEGF group and 37 mmHg (SD 9) in the control group. Data on mean baseline IOP were unavailable in the remaining two RCTs. </p> </section> <section id="CD007920-sec-0052"> <h5 class="title">Types of interventions</h5> <p>The anti‐VEGF medications the RCTs examined included intravitreal ranibizumab (<a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>; <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a>), bevacizumab (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>), and aflibercept (<a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a>). The adjunct treatments were PRP (as required: <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>; <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a>; <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a>) and PRP combined with an Ahmed glaucoma valve implant (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>). <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> used sham injections in the control group and intravitreal anti‐VEGF injections were allowed in the control group if re‐treatment criteria were met after week one. At week one, 81.5% of patients in the sham arm met re‐treatment criteria and received a single dose of anti‐VEGF injection. In all RCTs, participants were treated with anti‐glaucoma medications, as required, to improve control of their IOP. </p> </section> <section id="CD007920-sec-0053"> <h5 class="title">Types of outcomes </h5> <section id="CD007920-sec-0054"> <h6 class="title">Critical outcome</h6> <section id="CD007920-sec-0055"> <p><b>Proportion of participants who achieved control of IOP </b></p> <p>Of five RCTs, four reported achieving control of IOP using different definition at various time points (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>; <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>). <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> defined achieving control of IOP as (1) achieving a postoperative IOP between 6 mmHg and 21 mmHg, with or without anti‐glaucoma medications, and (2) IOP reduction of at least 30% from baseline, at 1 day, 1 week, 2 weeks, and 1, 3, 6, 12, 18, and 24 months. <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a> defined such an outcome as (1) for markedly effective: IOP &lt; 16 mmHg without further damage to the visual field or need for postoperative pharmacologic treatment for NVG; (2) effective: IOP 16 to 21 mmHg without further damage to the visual field and required postoperative local pharmacologic treatment at one month. <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a> defined achieving control of IOP as achieving an unmedicated IOP ≤ 21 mmHg but ≥ 10 mmHg, without the need for additional glaucoma surgery or visually devastating complications at 3, 5, 7, 10, and 15 days, and at 1, 3, 6, 9, 12 and 18 months. <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> reported the proportion of participants who achieved IOP ≤ 21 mmHg at weeks 1, 2, 5, 9, and 13.  </p> </section> </section> <section id="CD007920-sec-0056"> <h6 class="title">Important outcomes</h6> <section id="CD007920-sec-0057"> <p><b>Mean intraocular pressure</b></p> <p>All five RCTs reported mean IOP. <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> reported mean intraocular pressure at baseline, 1, 7, 15 days, and 1, 3, 6, 9, 12, 18, and 24 months. <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a> reported mean intraocular pressure at postoperative 1 month. <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a> reported such an outcome at 1, 3, 6 months, 1 year, and 18 months. <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a> reported the mean IOP immediately following treatment; however, the interpretation of the results is uncertain, because it is unclear whether this analysis accounted for the potential unit of analysis issues in this study. <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> examined the change in IOP from baseline to 1 week as the critical outcome, and reported the change in IOP from baseline to weeks 2, 5, 9, and 13 as the important outcomes. </p> </section> <section id="CD007920-sec-0058"> <p><b>Proportion of participants with improvement in visual acuity</b></p> <p>Of all included RCTs, only two RCTs reported the improvement in visual acuity at different time points. <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a> and <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a> reported the proportion of visual acuity improvement at one month and 18 months, respectively, without clearly specifying the definition of visual acuity improvement. <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> reported differences in postoperative visual acuity without specifying the measurement time. Likewise, <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a> reported the visual acuity outcome; however, the interpretation of such results is uncertain because it is unclear whether this analysis accounted for the potential unit of analysis issues and which unit of measurement was used for this visual acuity outcome.  </p> </section> <section id="CD007920-sec-0059"> <p><b>Proportion of participants with complete regression of new iris vessels</b></p> <p>Of five RCTs, three (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>, <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>) reported the proportion of participants with complete regression of new iris vessels at different time points. <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a> reported the complete regression of new vessels outcome in the anti‐VEGF medications arm at one week, but did not provide results for the control group. <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a> and <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> reported such an outcome at one month, and from 1.5 to 3 years, respectively. </p> </section> <section id="CD007920-sec-0060"> <p><b>Proportion of participants with relief of symptoms</b></p> <p>No RCTs reported on the proportion of participants with relief of pain and resolution of redness at any time points. </p> </section> <section id="CD007920-sec-0061"> <p><b>Adverse events</b></p> <p>We specified six adverse events to compare such effects of anti‐VEGFs in the protocol: proportion of participants with intraocular infection or inflammation (endophthalmitis), hypotony (IOP ≤ 6 mmHg), development of vitreous hemorrhage, tractional retinal detachment, no light perception, and other serious adverse events, including systemic thrombosis, stroke, and coronary thrombosis. Only <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a> reported the proportion of participants with hypotony. Only <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> documented occurrences of tractional retinal detachment. <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> was the only RCT that reported serious adverse events occurring during the non‐randomized period.  </p> </section> </section> </section> </section> <section id="CD007920-sec-0062"> <h4 class="title">Excluded studies</h4> <p>We excluded 27 studies after full‐text review (see reasons in the '<a href="./references#CD007920-sec-0114" title="">Characteristics of excluded studies</a>' table), including 26 studies identified from the updated searches and one study from the Characteristics of ongoing studies section of the previous review due to its inactive status since 2016 (<a href="./references#CD007920-bbs2-0022" title="NCT02914626. Intravitreal ranibizumab (Lucentis®) for neovascular glaucoma - a randomized controlled study. clinicaltrials.gov/ct2/show/NCT02914626 (first received 26 September 2016). ">NCT02914626</a>). </p> <p>In summary, of all 27 excluded studies, 14 studies were not RCTs, four studies did not include participants with NVG, three studies did not evaluate interventions eligible for this review, four studies did not evaluate comparator eligible for this review, and two studies were registered in a clinical trial register and listed as 'unknown/incomplete' for more than eight years. If these two incomplete studies are completed, or their status is updated, we will reassess them for eligibility in future versions of this review (<a href="./references#CD007920-bbs2-0011" title="EUCTR2007-000585-21-IE. Randomised controlled trial of intravitreal Bevacizumab vs. conventional treatment for rubeotic glaucoma. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007-000585-21-IE (first received 02 June 2007). ">EUCTR2007‐000585‐21‐IE</a> and <a href="./references#CD007920-bbs2-0022" title="NCT02914626. Intravitreal ranibizumab (Lucentis®) for neovascular glaucoma - a randomized controlled study. clinicaltrials.gov/ct2/show/NCT02914626 (first received 26 September 2016). ">NCT02914626</a>).<br/>  </p> </section> </section> <section id="CD007920-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD007920-fig-0002">Figure 2</a> presents our assessment of the risk of bias in the included RCTs. </p> <div class="figure" id="CD007920-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study" data-id="CD007920-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD007920-sec-0064"> <h4 class="title">Allocation</h4> <p>Most included RCTs had either low or unclear risk of bias for sequence generation and allocation concealment domains, except for <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a>, which was judged to have a high risk of bias for both domains. <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> described using a computer‐generated randomization table to generate the randomization sequence but did not describe how this sequence was concealed. <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a> and <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a> provided no information about generating the random sequence or concealment of allocation. <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> used stratified randomization with a 1:1 ratio and performed allocation concealment using an interactive voice response system. <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a> assigned participants to interventions based on a medical record number, which was not truly random. Accordingly, we assessed <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> as having low risk of bias for sequence generation and unclear risk of bias for allocation concealment; we assessed <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a> and <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a> as having unclear risk of bias for both sequence generation and allocation concealment; we assessed <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> as having low risk of bias for both sequence generation and allocation concealment; we assessed <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a> as having high risk of bias for both sequence generation and allocation concealment. </p> </section> <section id="CD007920-sec-0065"> <h4 class="title">Blinding</h4> <p>We assessed <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a> and <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> as having low risk of bias for masking of participants and personnel and assessed the remaining three studies (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>) as having unclear risk of bias for masking of participants and personnel because they did not provide sufficient information. In terms of masking of outcome assessment, <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> and <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> commented that the IOP assessors did not know which group participants were assigned to; thus, we assessed these two RCTs as having low risk of bias for masking of outcome assessors for the primary outcome. We assessed all the remaining four RCTs (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>; <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>) as having unclear risk of bias for masking of outcome assessment because they did not provide sufficient information.  </p> </section> <section id="CD007920-sec-0066"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a> as having low risk of bias for incomplete outcome data as the authors reported data for all participants included in the study. However, we assessed <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> as having high risk of bias for incomplete outcome data as 22% of the participants did not complete the RCT mainly due to progressive diseases, and such losses of follow‐up due to progressive diseases were unbalanced between groups. Since the RCT handled the missing data using last‐observation‐carried‐forward, it could bias the results. For the remaining RCTs (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>), we assessed them as having unclear risk of bias for incomplete outcome data because we did not have sufficient information to permit judgment. In <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>, the data for five participants (25%) in each arm were not included at the one‐year follow‐up, but the reasons for exclusion were not reported. </p> </section> <section id="CD007920-sec-0067"> <h4 class="title">Selective reporting</h4> <p>We assessed <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> and <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> as having low risk of bias for selective reporting of outcomes because the full‐text reports included all outcomes specified on clinical trial registries. We judged the remaining three RCTs (<a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>; <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>) as having unclear risk of bias for this domain for because the protocols or trial registrations were not available. </p> </section> <section id="CD007920-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <p>We assessed <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> as having high risk of bias for other potential sources of bias for three reasons: 1) IOP was assessed using applanation tonometry or Tono‐Pen, but no further details were reported about the number of patients assessed with each of them. It is known that these two tonometers provide measurements that are not interchangeable; 2) the funding was sponsored by a pharmaceutical company, which was involved in study design, data collection, data analysis and interpretation, review preparation, and manuscript submission; and 3) participants who were randomized to sham injection could receive aflibercept injections after one week. We assessed the remaining four RCTs as having unclear risk of bias for other potential sources of bias: <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> did not report conflicts of interest; sources of funding were unclear in <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>, <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a>, and <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>. </p> </section> </section> <section id="CD007920-sec-0069"> <h3 class="title" id="CD007920-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD007920-tbl-0001"><b>Summary of findings 1</b> Anti‐VEGF versus no anti‐VEGF for neovascular glaucoma</a> </p> <section id="CD007920-sec-0070"> <h4 class="title">Critical outcome</h4> <section id="CD007920-sec-0071"> <h5 class="title">Proportion of participants who achieved control of IOP </h5> <p>Four RCTs reported the proportion of participants achieving IOP ≤ 21 mmHg with or without anti‐glaucoma medications (i.e. success) at one month or beyond (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>; <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>). We did not conduct meta‐analyses, because of small numbers of included RCTs for each time point. </p> <p>Two RCTs (<a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a> and <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a>) reported our critical time point, which was at four to six weeks. However, <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> applied a non‐randomized design during that time period. <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a> found that the anti‐VEGF group had a 1.3‐fold higher chance of achieving control of IOP at one month than the non‐anti‐VEGF group (RR 1.32, 95% 1.10 to 1.59; 93 participants; <a href="./references#CD007920-fig-0003" title="">Analysis 1.1</a>). We graded certainty of the evidence as low due to limitations in the study design due to insufficient information to permit judgment (‐1) and imprecision of results due to the small sample size (‐1) (<a href="./full#CD007920-tbl-0001">summary of findings Table 1</a>). </p> <p>The two remaining RCTs (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> and <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>) reported time points at one year or beyond. <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> found that anti‐VEGFs may increase the chance of achieving control of IOP by one‐fold as compared with no anti‐VEGFs (RR 1.08; 95% CI: 0.67 to 1.75; 40 participants; range 1.5 years to 3 years; <a href="./references#CD007920-fig-0003" title="">Analysis 1.1</a>). However, <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a> reported that the anti‐VEGF group had a three times higher chance of achieving control of IOP at one year (RR 3.00; 95% CI: 1.35 to 6.68; 40 participants; <a href="./references#CD007920-fig-0003" title="">Analysis 1.1</a>). </p> </section> </section> <section id="CD007920-sec-0072"> <h4 class="title">Important outcomes</h4> <section id="CD007920-sec-0073"> <h5 class="title">Mean intraocular pressure</h5> <p>All five RCTs reported mean IOP, ranging from one week to 18 months (<a href="#CD007920-tbl-0002">Table 1</a>; <a href="#CD007920-tbl-0003">Table 2</a>), three (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>) of which reported mean IOP at four to six weeks (<a href="./references#CD007920-fig-0004" title="">Analysis 1.2</a>). Based on data from 173 participants, anti‐VEGFs decreased the mean IOP by 6.37 mmHg (95% CI: ‐10.09 to ‐2.65; P = 0.0008) as compared with no anti‐VEGFs (I<sup>2</sup> = 95%, P &lt; 0.00001), suggesting that anti‐VEGFs may reduce mean IOP at four to six weeks when compared with no anti‐VEGFs. We graded the certainty of the evidence for this outcome as very low due to unclear risk of bias (‐1), imprecision of results due to small sample size (‐1), and inconsistency due to high statistical heterogeneity (‐1) (<a href="./full#CD007920-tbl-0001">summary of findings Table 1</a>). </p> <div class="table" id="CD007920-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Arcieri 2015 – IOP at baseline and follow‐up</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time point</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>IVB + PRP + AGV IOP<br/>(mean ± SD)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>PRP + AGV (control)<br/>IOP (mean ± SD)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.10 ± 13.33 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.35 ± 10.34 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6454</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.68 ± 5.74 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.85 ± 6.74 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9348</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.35 ± 4.76 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.45 ± 5.77 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5148</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.00 ± 6.13 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.50 ± 7.34 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2498</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.45 ± 4.65 (N = 20 )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.05 ± 6.16 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3597</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.30 ± 6.55 (N = 18 )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.33 ± 5.44 (N = 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9866</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.78 ± 7.47 (N = 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.33 ± 4.35 (N = 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3827</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.31 ± 8.93 (N = 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.17 ± 4.60 (N = 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8898</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.40 ± 9.99 (N = 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.00 ± 3.98 (N = 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4598</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.57 ± 1.72 (N = 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.37 ± 1.06 (N = 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0002</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.43 ± 0.53 (N = 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.67 ± 4.40 (N = 12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0526</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>AGV</b> : Ahmed glaucoma valve<br/><b>IOP</b> : intraocular pressure (mmHg)<br/><b>IVB</b> : intravitreal bevacizumab<br/><b>N</b> : number of eyes<br/><b>PRP</b> : pan retinal photocoagulation<br/><b>SD</b>: standard deviation </p> </div> </div> <div class="table" id="CD007920-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Mahdy 2012 – IOP at baseline and follow‐up</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time point</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Avastin + PRP + AGV<br/>(N = 20 eyes)<br/>IOP (mean ± SD)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>PRP + AGV (control)<br/>(N = 20 eyes)<br/>IOP (mean ± SD)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.4 ± 4.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.5 ± 7.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 week postoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.0 ± 3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.5 ± 4.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month postoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 ± 2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5 ± 2.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months postoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 ± 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 ± 1.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months postoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 ± 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 ± 3.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months postoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 ± 8.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 months postoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 ± 4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 ± 6.5</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>AGV:</b> Ahmed glaucoma valve<br/><b>IOP:</b> intraocular pressure (mmHg)<br/><b>N:</b> number of eyes<br/><b>PRP:</b> pan retinal photocoagulation<br/><b>SD:</b> standard deviation </p> </div> </div> <p>Two (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>) of the five RCTs reported mean IOP at three months, six months, one year, and more than one year (<a href="./references#CD007920-fig-0004" title="">Analysis 1.2</a>). Based on the combined estimate from 75 participants, anti‐VEGFs may decrease mean IOP by 4.25 mmHg (95% CI ‐12.05 to 3.54, P = 0.28; I<sup>2</sup> = 93%, P for I<sup>2</sup> = 0.0002) at three months, by 5.93 mmHg (95% CI ‐18.13 to 6.26, P = 0.34; I<sup>2</sup> = 97%, P for I<sup>2</sup> &lt; 0.00001) at six months, by 5.36 mmHg (95% CI ‐18.50 to 7.77, P = 0.42; I<sup>2</sup> = 92%, P for I<sup>2</sup> = 0.0003) at one year, and by 7.05 mmHg (95% CI ‐16.61 to 2.51, P = 0.15; I<sup>2</sup> = 95%, P for I<sup>2</sup> &lt; 0.00001) at more than one year when compared with no anti‐VEGF. However, these results remain uncertain.  </p> </section> <section id="CD007920-sec-0074"> <h5 class="title">Proportion of participants with improvement in visual acuity</h5> <p>Two RCTs reported the proportion of participants who achieved improvement in visual acuity at one month, or at 18 months (<a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>). </p> <p><a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a> was the only RCT that reported this outcome at one month. Participants receiving anti‐VEGFs had 2.6 times higher chance of improving visual acuity when compared with those not receiving anti‐VEGFs (RR 2.55, 95% CI 1.60 to 4.08; 93 participants; <a href="./references#CD007920-fig-0005" title="">Analysis 1.3</a>); however, the study did not clearly specify a definition of the improvement in visual acuity. We graded the certainty of the evidence for this outcome measured at four to six weeks as very low due to imprecision (‐1), indirectness (‐1) of results, as well as limitations in the design due to insufficient information to permit judgment (‐1) (<a href="./full#CD007920-tbl-0001">summary of findings Table 1</a>). </p> <p><a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a> reported this outcome at 18 months. They found that the anti‐VEGF group had a four‐fold higher chance of improving visual acuity than the non‐anti‐VEGF group (RR 4.00, 95% CI 1.33 to 12.05; 40 participants; <a href="./references#CD007920-fig-0005" title="">Analysis 1.3</a>). <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> reported no statistically significant difference in postoperative visual acuity (P &gt; 0.1270), but did not specify the measurement time point. <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a> reported that visual acuity was higher in the anti‐VEGF group compared to the non‐anti‐VEGF group, but the results were uncertain, due to the limitations of study design. </p> </section> <section id="CD007920-sec-0075"> <h5 class="title">Proportion of participants with complete regression of new iris vessels</h5> <p>All five RCTs noted that a larger proportion of participants in the anti‐VEGF medications arm had more regression of iris new vessels at various time points. Three out of five  (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>, <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>) reported on the proportion of participants with complete regression of new iris vessels at 1 week, 1 month, and from 1.5 to 3 years, respectively.  </p> <p><a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a> was the only RCT that reported this outcome at one month. Anti‐VEGFs had a 2.6 times higher chance of complete regression of new iris vessels when compared with no anti‐VEGFs (RR 2.63, 95% CI 1.65 to 4.18; 93 participants; <a href="./references#CD007920-fig-0006" title="">Analysis 1.4</a>). We graded the certainty of the evidence for this outcome measured at four to six weeks as low due to imprecision from a small sample size (‐1) and limitations in the design due to insufficient information to permit judgment (‐1) (<a href="./full#CD007920-tbl-0001">summary of findings Table 1</a>). </p> <p><a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> reported the proportion of participants with complete regression of new iris vessels at more than one year, and found that the anti‐VEGF group had 3.2 times higher chance of complete regression of iris new vessels when compared with the non‐anti‐VEGF group (RR 3.20, 95% CI 1.45 to 7.05; 40 participants; <a href="./references#CD007920-fig-0006" title="">Analysis 1.4</a>)  </p> </section> <section id="CD007920-sec-0076"> <h5 class="title">Proportion of participants with relief of symptoms</h5> <p>No RCTs reported on the proportion of participants with relief of pain and resolution of redness at any time points. </p> </section> <section id="CD007920-sec-0077"> <h5 class="title">Adverse events</h5> <section id="CD007920-sec-0078"> <h6 class="title">Proportion of participants with intraocular infection or inflammation (endophthalmitis)</h6> <p>No RCTs reported on the proportion of participants with intraocular infection or inflammation (endophthalmitis) at any time points. </p> </section> <section id="CD007920-sec-0079"> <h6 class="title">Proportion of participants with hypotony (IOP ≤ 6 mmHg)</h6> <p>Only <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a> reported incidents of hypotony. The estimated RR was 0.67 (95% CI: 0.12 to 3.57; 40 participants; <a href="./references#CD007920-fig-0007" title="">Analysis 1.5</a>), suggesting no evidence of differences in hypotony incidence comparing anti‐VEGFs with no anti‐VEGFs. We graded the certainty of the evidence as low due to limitations in the design due to insufficient information to permit judgment (‐1) and imprecision (‐1) of results from a small sample size (<a href="./full#CD007920-tbl-0001">summary of findings Table 1</a>).  </p> </section> <section id="CD007920-sec-0080"> <h6 class="title">Proportion of participants with development of vitreous hemorrhage.</h6> <p>No RCTs reported on the proportion of participants with vitreous hemorrhage at any time points. </p> </section> <section id="CD007920-sec-0081"> <h6 class="title">Proportion of participants with tractional retinal detachment</h6> <p>Only <a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a> reported the incident of tractional retinal detachment. The estimated RR was 0.33 (95% CI: 0.01 to 7.72; 40 participants; <a href="./references#CD007920-fig-0007" title="">Analysis 1.5</a>), suggesting no evidence of differences in tractional retinal detachment incidence comparing anti‐VEGFs with no anti‐VEGFs. We graded the certainty of the evidence as low due to limitations in the design due to insufficient information to permit judgment (‐1) and imprecision (‐1) of results from a small sample size (<a href="./full#CD007920-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD007920-sec-0082"> <h6 class="title">Proportion of participants with no light perception</h6> <p>No RCTs reported on the proportion of participants with no light perception at any time points. </p> </section> </section> <section id="CD007920-sec-0083"> <h5 class="title">Proportion of participants with serious adverse events (e.g., systemic thrombosis, stroke, and coronary thrombosis) </h5> <p>No RCTs reported incidents of serious adverse events. <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> reported that severe ocular treatment‐emergent adverse events occurred in both groups during the non‐randomized period, where participants could receive both sham injection and aflibercept injection if the re‐treatment criteria were met. During the non‐randomized period, three severe ocular treatment‐emergent adverse events were reported. For the anti‐VEGF medications arm, one participant (3.7%) developed retinal artery occlusion and one (3.7%) developed retinal vein occlusion. For the sham/anti‐VEGF arm, one (3.7%) developed diabetic retinopathy. In addition, one participant (3.7%) in the sham/anti‐VEGF arm developed nonfatal myocardial infarction during this non‐randomized study period. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007920-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007920-sec-0084">English</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007920-sec-0204">Français</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007920-sec-0084"></div> <section id="CD007920-sec-0085"> <h3 class="title" id="CD007920-sec-0085">Summary of main results</h3> <p>We included five eligible RCTs (<a href="./references#CD007920-bbs2-0001" title="ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). ArcieriES , PaulaJS , JorgeR , BarellaKA , ArcieriRS , SecchesDJ , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica2015;93(1):e1-6. ArcieriES , SecchesDJL , PaulaJS , BarellaKA , ArcieriRS , JorgeR , et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. Investigative Ophthalmology &amp; Visual Science2010;51:627 (Poster A471). ">Arcieri 2015</a>; <a href="./references#CD007920-bbs2-0002" title="DengY , Zhang J-S. Anti-VEGF medicine with PRP for neovascular glaucoma. International Eye Science 2018;18(10):1855-8. ">Deng 2018</a>; <a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a>; <a href="./references#CD007920-bbs2-0004" title="JiangWP , LuSS , JinY . Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science2015;15(10):1763-5. ">Jiang 2015</a>; <a href="./references#CD007920-bbs2-0005" title="MahdyRA , NadaWM , FawzyKM , AlnasharHY , AlmosalamySM . Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma2013;22(9):768-72. ">Mahdy 2013</a>) in this updated review. The five RCTs, taken together, randomized 356 eyes of 353 adult participants to treatment with either anti‐VEGF medications or to treatment without anti‐VEGF medications. When compared with no anti‐VEGFs, anti‐VEGFs may be effective in achieving control of IOP, improving visual acuity, and achieving complete regression of new iris vessels, with very low to low certainty of evidence. Likewise, low certainty of evidence suggested that anti‐VEGFs may be effective in reducing mean IOP in the short term (four to six weeks) while the long‐term effects remain uncertain. Anti‐VEGFs had a comparable risk of hypotony and tractional retinal detachment to no anti‐VEGFs; however, the certainty of evidence for both adverse outcomes was low due to insufficient information to permit judgment.  </p> </section> <section id="CD007920-sec-0086"> <h3 class="title" id="CD007920-sec-0086">Overall completeness and applicability of evidence</h3> <p>Of the five RCTs included, three were available through journal publications and trial registries. Four included RCTs were conducted in different geographic locations, including Brazil, China, Egypt, and Japan. The applicability to other populations including Caucasians is uncertain. All included RCTs recruited middle‐aged male and female participants, which were well representative of the typical NVG patient population (<a href="./references#CD007920-bbs2-0065" title="RodriguesGB , AbeRY , ZangalliC , SodreSL , DoniniFA , CostaDC , et al. Neovascular glaucoma: a review. International Journal of Retina &amp; Vitreous2016;2:26. [DOI: 10.1186/s40942-016-0051-x]">Rodrigues 2016</a>). Regarding the interventions, three main anti‐VEGF medications were used across RCTs, including ranibizumab, bevacizumab, and aflibercept, which covered all available traditional options on the market (<a href="./references#CD007920-bbs2-0035" title="Andrés-GuerreroV , Perucho-GonzálezL , García-FeijooJ , Morales-FernándezL , Saenz-FrancésF , Herrero-VanrellR , et al . Current perspectives on the use of anti-VEGF drugs as adjuvant therapy in glaucoma. Advances in Therapy2017;34(2):378-95. [DOI: 10.1007/s12325-016-0461-z]">Andrés‐Guerrero 2017</a>). The adjunct treatment was either PRP alone, or with a glaucoma drainage device using the Ahmed glaucoma valve implantation, the first treatment option for refractory glaucoma (<a href="./references#CD007920-bbs2-0065" title="RodriguesGB , AbeRY , ZangalliC , SodreSL , DoniniFA , CostaDC , et al. Neovascular glaucoma: a review. International Journal of Retina &amp; Vitreous2016;2:26. [DOI: 10.1186/s40942-016-0051-x]">Rodrigues 2016</a>). All RCTs allocated no pharmacologic treatment to the control group, except for one RCT that allowed the control group to receive anti‐VEGFs if re‐treatment criteria were met after the first week. For the review's critical outcome, achieving control of IOP, each RCT reported such an outcome at different time points and using different definitions, which did not permit pooling via meta‐analyses. Likewise, similar issues occurred for the important outcomes of improvement in visual acuity and complete regression of new iris vessels. For the most commonly reported review outcome, mean IOP, most RCTs did not specify the method of IOP measurement. Such variations in population's ethnicities, pharmacologic treatment, adjunct treatment, as well as insufficient information on outcome measurements across included RCTs are possibly potential sources of between‐study heterogeneity. Therefore, these factors should be considered when interpreting the evidence.  </p> </section> <section id="CD007920-sec-0087"> <h3 class="title" id="CD007920-sec-0087">Quality of the evidence</h3> <p>We graded the certainty of the evidence as low to very low for all outcomes reported by the included studies, mostly because of small sample size and unclear risk of bias domains due to insufficient information to permit judgment. No relevant and sufficient data were available for meta‐analysis for all but one outcome (mean IOP control) which we specified as a critical outcome for this review. </p> </section> <section id="CD007920-sec-0088"> <h3 class="title" id="CD007920-sec-0088">Potential biases in the review process</h3> <p>We followed standard Cochrane methods outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to minimize potential for introducing bias in the review process (<a href="./references#CD007920-bbs2-0050" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011a</a>). We worked with an information specialist to design a comprehensive search strategy and we searched multiple electronic databases, including clinical trial registries. We did not limit our search by date or by language. The review team constituted content experts and methodologists; two review authors completed tasks, such as screening references for inclusion and assessing studies, in duplicate, in order to minimize errors and bias. </p> </section> <section id="CD007920-sec-0089"> <h3 class="title" id="CD007920-sec-0089">Agreements and disagreements with other studies or reviews</h3> <p>This review showed better IOP reduction and regression of iris neovascularization in the short term with the use of anti‐VEGF medications in NVG, which were consistent with other non‐randomized studies (<a href="./references#CD007920-bbs2-0046" title="GroverS , GuptaS , SharmaR , BrarVS , ChalamKV . Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. British Journal of Ophthalmology2009;93(2):273-4.">Grover 2009</a>; <a href="./references#CD007920-bbs2-0047" title="GuptaV ,  JhaR ,  RaoA ,  KongG ,  SihotaR . The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. European Journal of Ophthalmology2009;19(3):435–41.">Gupta 2009</a>; <a href="./references#CD007920-bbs2-0056" title="InataniM ,  HigashideT ,  MatsushitaK ,  NagasatoD ,  TakagiH ,  UekiM ,  et al . Efficacy and safety of intravitreal aflibercept injection in Japanese patients with neovascular glaucoma: outcomes from the VENERA study. Advances in Therapy2021;38(2):1106-15. [DOI: 10.1007/s12325-020-01580-y]">Inatani 2020</a>). Trials included in this review reported varying results in controlling IOP with the use of anti‐VEGF medications in the long term. Published meta‐analyses showed inconsistent findings, possibly due to methodological limitations of these reviews (<a href="./references#CD007920-bbs2-0042" title="DongZ , GongJ , LiaoR , XuS . Effectiveness of multiple therapeutic strategies in neovascular glaucoma patients: a PRISMA-compliant network meta-analysis. Medicine2018;97(14):e9897. [PMID: 29620670]">Dong 2018</a>; <a href="./references#CD007920-bbs2-0053" title="HwangHB , HanJW , YimHB , LeeNY . Beneficial effects of adjuvant intravitreal bevacizumab injection on outcomes of Ahmed glaucoma valve implantation in patients with neovascular glaucoma: systematic literature review. Journal of Ocular Pharmacology and Therapeutics2015;31(4):198-203. [PMID: 25714761]">Hwang 2015</a>; <a href="./references#CD007920-bbs2-0054" title="HwangHB , LeeNY . Effect of anti-vascular endothelial growth factor on the surgical outcome of neovascular glaucoma: an overview and meta-analysis. Medicine2021;100(39):e27326. [DOI: doi:10.1097/MD.0000000000027326]">Hwang 2021</a>; <a href="./references#CD007920-bbs2-0077" title="ZhouM , XuX , ZhangX , SunX . Clinical outcomes of Ahmed glaucoma valve implantation with or without intravitreal bevacizumab pretreatment for neovascular glaucoma: a systematic review and meta-analysis. Journal of Glaucoma2016;25(7):551-7. [PMID: 25719237]">Zhou 2016</a>). <a href="./references#CD007920-bbs2-0042" title="DongZ , GongJ , LiaoR , XuS . Effectiveness of multiple therapeutic strategies in neovascular glaucoma patients: a PRISMA-compliant network meta-analysis. Medicine2018;97(14):e9897. [PMID: 29620670]">Dong 2018</a> conducted incomprehensive literature searches while <a href="./references#CD007920-bbs2-0054" title="HwangHB , LeeNY . Effect of anti-vascular endothelial growth factor on the surgical outcome of neovascular glaucoma: an overview and meta-analysis. Medicine2021;100(39):e27326. [DOI: doi:10.1097/MD.0000000000027326]">Hwang 2021</a> focused only on bevacizumab as the adjuvant pharmacologic treatment, included not only RCTs but also observational studies, and used inappropriate statistical methods for analyzing their data.  </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007920-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/urn:x-wiley:14651858:media:CD007920:CD007920-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram" data-id="CD007920-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_t/tCD007920-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/full#CD007920-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007920-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/urn:x-wiley:14651858:media:CD007920:CD007920-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study" data-id="CD007920-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_t/tCD007920-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/full#CD007920-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007920-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/urn:x-wiley:14651858:media:CD007920:CD007920-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐VEGF medications vs no anti‐VEGF medications, Outcome 1: Proportion of participants who achieved control of IOP" data-id="CD007920-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_t/tCD007920-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Anti‐VEGF medications vs no anti‐VEGF medications, Outcome 1: Proportion of participants who achieved control of IOP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/references#CD007920-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007920-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/urn:x-wiley:14651858:media:CD007920:CD007920-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐VEGF medications vs no anti‐VEGF medications, Outcome 2: Mean intraocular pressure" data-id="CD007920-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_t/tCD007920-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Anti‐VEGF medications vs no anti‐VEGF medications, Outcome 2: Mean intraocular pressure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/references#CD007920-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007920-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/urn:x-wiley:14651858:media:CD007920:CD007920-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐VEGF medications vs no anti‐VEGF medications, Outcome 3: Proportion of participants with improvement in visual acuity" data-id="CD007920-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_t/tCD007920-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Anti‐VEGF medications vs no anti‐VEGF medications, Outcome 3: Proportion of participants with improvement in visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/references#CD007920-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007920-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/urn:x-wiley:14651858:media:CD007920:CD007920-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐VEGF medications vs no anti‐VEGF medications, Outcome 4: Proportion of participants with complete regression of new iris vessels" data-id="CD007920-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_t/tCD007920-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Anti‐VEGF medications vs no anti‐VEGF medications, Outcome 4: Proportion of participants with complete regression of new iris vessels </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/references#CD007920-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007920-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/urn:x-wiley:14651858:media:CD007920:CD007920-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐VEGF medications vs no anti‐VEGF medications, Outcome 5: Complications" data-id="CD007920-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_t/tCD007920-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Anti‐VEGF medications vs no anti‐VEGF medications, Outcome 5: Complications</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/references#CD007920-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/media/CDSR/CD007920/image_n/nCD007920-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007920-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Anti‐VEGF versus no anti‐VEGF for neovascular glaucoma</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Anti‐VEGF medication compared with no anti‐VEGF medication for neovascular glaucoma</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with neovascular glaucoma<br/><b>Setting:</b> ophthalmology hospital or clinic<br/><b>Intervention:</b> intravitreal anti‐VEGF medication injection<br/><b>Comparison:</b> no anti‐VEGF medication </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no anti‐VEGF</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with anti‐VEGF</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of participants with IOP ≤ 21 mmHg, with or without ocular hypotensive medications, </p> <p>4 to 6 weeks follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>723 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>954 per 1000</b> (795 to 1150) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.32</b><br/>(95% CI 1.10 to 1.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean IOP, 4 to 6 weeks follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean IOP in the no anti‐VEGF group was <b>24.2 mm Hg</b>, </p> <p>ranged from 23.6 to 24.8 mm Hg</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean IOP in the anti‐VEGF group was <b>17.8 mm Hg</b>, </p> <p>ranged from 14.1 to 21.6 mm Hg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD ‐6.37</b> (95% CI ‐10.09 to ‐2.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>173 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of participants with improvement in visual acuity of 2 ETDRS lines or 0.2 logMAR units, 4 to 6 weeks follow‐up </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>298 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>760 per 1000</b> (477 to 1216) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.55</b><br/>(95% CI 1.60 to 4.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The trial did not clearly specify a definition of the improvement in visual acuity</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of participants with complete regression of new iris vessels,</p> <p>4 to 6 weeks follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>298 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>784 per 1000</b> (492 to 1246) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.63</b><br/>(95% CI 1.65 to 4.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝ Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with relief of pain and resolution of redness,</p> <p>1 year follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p> </p> <p> </p> <p>Included studies did not report data for this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Proportion of participants with adverse events at</p> <p>various follow‐up times</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Hypotony (IOP ≤ 6 mmHg)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p><b>15 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 100</b> (2 to 54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.67</b><br/>(95% CI 0.12 to 3.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The follow‐up period was 18 months.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Tractional retinal detachment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>5 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>2 per 100</b> (0 to 39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.33</b><br/>(95% CI 0.01 to 7.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The follow‐up period was 24 months.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Serious adverse events (e.g. systemic thrombosis, stroke, and coronary thrombosis)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Included studies did not report data for this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007920-bbs2-0003" title="HigashideT , InataniM , MatsushitaK , UekiM , KubotaT , IwamotoY , et al. Efficacy and safety of intravitreal aflibercept injection (IAI) in neovascular glaucoma (NVG): the VEGA study. Investigative Ophthalmology &amp; Visual Science2019;60:2398. InataniM , HigashideT , MatsushitaK , MikiA , UekiM , IwamotoY , et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Advances in Therapy 2021;38(2):1116-29. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). ">Inatani 2021</a> reported an occurrence of serious ocular treatment‐emergent adverse events in both groups during the non‐randomized period, where participants could receive both sham injection and aflibercept injection if the re‐treatment criteria were met.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>Anti‐VEGF:</b> anti‐vascular endothelial growth factor; <b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>MD:</b> mean difference; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded (‐1) due to limitations in the design<br/><sup>b</sup>Downgraded (‐1) due to imprecision of results </p> <p><sup>c</sup>Downgraded (‐1) due to inconsistency<br/><sup>d</sup>Downgraded (‐1) due to indirectness of evidence </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Anti‐VEGF versus no anti‐VEGF for neovascular glaucoma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/full#CD007920-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007920-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Arcieri 2015 – IOP at baseline and follow‐up</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time point</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>IVB + PRP + AGV IOP<br/>(mean ± SD)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>PRP + AGV (control)<br/>IOP (mean ± SD)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.10 ± 13.33 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.35 ± 10.34 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6454</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.68 ± 5.74 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.85 ± 6.74 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9348</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.35 ± 4.76 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.45 ± 5.77 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5148</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.00 ± 6.13 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.50 ± 7.34 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2498</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.45 ± 4.65 (N = 20 )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.05 ± 6.16 (N = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3597</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.30 ± 6.55 (N = 18 )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.33 ± 5.44 (N = 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9866</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.78 ± 7.47 (N = 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.33 ± 4.35 (N = 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3827</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.31 ± 8.93 (N = 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.17 ± 4.60 (N = 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8898</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.40 ± 9.99 (N = 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.00 ± 3.98 (N = 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4598</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.57 ± 1.72 (N = 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.37 ± 1.06 (N = 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0002</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.43 ± 0.53 (N = 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.67 ± 4.40 (N = 12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0526</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><b>AGV</b> : Ahmed glaucoma valve<br/><b>IOP</b> : intraocular pressure (mmHg)<br/><b>IVB</b> : intravitreal bevacizumab<br/><b>N</b> : number of eyes<br/><b>PRP</b> : pan retinal photocoagulation<br/><b>SD</b>: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Arcieri 2015 – IOP at baseline and follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/full#CD007920-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007920-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Mahdy 2012 – IOP at baseline and follow‐up</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time point</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Avastin + PRP + AGV<br/>(N = 20 eyes)<br/>IOP (mean ± SD)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>PRP + AGV (control)<br/>(N = 20 eyes)<br/>IOP (mean ± SD)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.4 ± 4.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.5 ± 7.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 week postoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.0 ± 3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.5 ± 4.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month postoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 ± 2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5 ± 2.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months postoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 ± 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 ± 1.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months postoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 ± 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 ± 3.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months postoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 ± 8.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 months postoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 ± 4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 ± 6.5</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><b>AGV:</b> Ahmed glaucoma valve<br/><b>IOP:</b> intraocular pressure (mmHg)<br/><b>N:</b> number of eyes<br/><b>PRP:</b> pan retinal photocoagulation<br/><b>SD:</b> standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Mahdy 2012 – IOP at baseline and follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/full#CD007920-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007920-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐VEGF medications vs no anti‐VEGF medications</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Proportion of participants who achieved control of IOP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 At 4 to 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 At 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 More than 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Mean intraocular pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 At 4 to 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.37 [‐10.09, ‐2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.25 [‐12.05, 3.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.93 [‐18.13, 6.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 At 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.36 [‐18.50, 7.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.5 More than 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.05 [‐16.61, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Proportion of participants with improvement in visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 At 4 to 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 More than 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Proportion of participants with complete regression of new iris vessels <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 At 4 to 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 More than 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Hypotony (IOP ≤ 6 mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Tractional retinal detachment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐VEGF medications vs no anti‐VEGF medications</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007920.pub4/references#CD007920-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007920.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007920-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007920-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007920-note-0008">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD007920-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD007920-note-0009">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007920-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007920\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007920\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007920\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007920\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007920\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007920.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007920.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007920.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007920.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007920.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725917891"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007920.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725917895"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007920.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e86f16ffa9371',t:'MTc0MDcyNTkxOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 